A persistent clinical misunderstanding threatens optimal cardiovascular and kidney care for millions with chronic conditions. Medications that could extend lives and prevent hospitalizations are being withheld based on an incorrect safety assessment that confuses correlation with causation.
Renin-angiotensin system inhibitors—including ACE inhibitors and ARBs—face widespread mislabeling as kidney-damaging despite robust evidence demonstrating protective effects. These medications reduce mortality in heart failure patients, slow chronic kidney disease progression, and decrease hospitalizations across multiple conditions. The nephrotoxicity myth stems from observing acute kidney injury in patients taking these drugs, yet the underlying diseases being treated—diabetes, heart failure, and existing kidney disease—are the actual culprits driving kidney dysfunction.
This mischaracterization represents a critical failure in medical risk assessment with real-world consequences. When clinicians avoid prescribing RAS inhibitors due to unfounded toxicity concerns, patients lose access to therapies with demonstrated survival benefits. The phenomenon mirrors historical medical reversals where beneficial treatments were abandoned based on incomplete understanding of mechanism versus association. Current evidence overwhelmingly supports RAS inhibition as renoprotective rather than harmful, particularly for patients with proteinuria and reduced heart function. The clinical imperative requires immediate correction of this therapeutic misconception. Healthcare systems must prioritize education distinguishing between medications that cause organ damage versus those that treat conditions associated with organ complications, ensuring evidence-based prescribing prevails over perpetuated myths.